New AI Method Explains Why a Treatment Works for Some, Not Others

In medicine and marketing, the big question is rarely "does this work?" It is "who does this work for?" A drug that helps half of patients and does nothing for the other half is expensive and potentially harmful if you cannot tell the two groups apart. Until now, AI tools that predict individual results were good at guessing but bad at explaining. They could say "you will improve" without saying why, which makes doctors and managers nervous about acting on it.

The new method, from Nicolas Alexander Ihlo and Merle Behr, is a small tweak to a familiar tool. Random forests are a common prediction technique: they build hundreds of simple decision trees, each one asking yes/no questions about a person (age? blood pressure? past purchases?), and then average the answers. This version changes just one thing — the rule each tree uses to decide where to split people into groups. It uses two rules at once: one that hunts for the people who benefit more, and one that cancels out misleading patterns in the data.

That second rule matters a lot. In real life, sicker patients often get a drug more often, so the drug looks useless or harmful even when it helps. The new method automatically separates those confusing factors from the ones that genuinely change how well a treatment works. And because the explanation comes straight from the tree's own structure, you do not need a separate, complicated step to interpret the results afterward.

In simulated tests — computer-generated data where researchers know the true answer — the method matched or beat existing approaches while being far easier to understand. The catch: this is an early academic paper, posted online without full peer review, and tested mostly on simulated data. Real-world records are messier. It is a promising step toward personalized medicine and smarter marketing, not a finished product you can use tomorrow.